Ivonescimab
Ivonescimab is a pharmaceutical drug with 57 clinical trials. Currently 37 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
16
Early Stage
40
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
50.0%
1 of 2 finished
50.0%
1 ended early
37
trials recruiting
57
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Clinical Trials (57)
A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer
Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Ivonescimab for the Treatment of Thymic Cancer
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 57